CVS Health set to report earnings as analysts eye GLP-1 momentum

CVS Health is scheduled to release its second-quarter earnings, with analysts keenly focused on the impact of the company's recent expansion into GLP-1 medications. The company is expected to report modest year-over-year growth in earnings and revenue, but a sequential decline from the previous quarter. Investors will also monitor GLP-1 program adoption metrics, margin trends in its Aetna health insurance business, and guidance for the remainder of 2026 and 2027.